Evaluation of Safety and Tolerability of MK-1045 in Lupus and Rheumatoid Arthritis Patients

This clinical trial focuses on a medication named MK-1045, which is being tested in individuals with lupus and rheumatoid arthritis (RA). The primary aim of this study is to understand the safety of MK-1045 and how well it is tolerated by participants when given in different doses. The importance of this study lies in its potential to uncover a new treatment option for these conditions, which could help improve patient care and address current treatment challenges. During this trial, participants will receive MK-1045 in varying doses. The study measures the results by tracking the number of participants who experience unfavorable effects known as Adverse Events (AEs). These AEs could be any unfavorable sign, symptom, disease, or worsening of an existing condition that occurs during the study, regardless of whether it's directly caused by the treatment. The study also records the number of participants who discontinue the study drug due to an AE. This information helps researchers evaluate the safety and tolerability of MK-1045.